Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ABCN TSE:CXR NYSE:FRX TSE:PLI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsCXRConcordia InternationalC$0.00C$19.02▼C$417.00C$1.22BN/A4,054 shs73,541 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsPLIProMetic Life SciencesC$0.00C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%CXRConcordia International0.00%0.00%0.00%0.00%0.00%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsCXRConcordia InternationalC$0.00C$19.02▼C$417.00C$1.22BN/A4,054 shs73,541 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsPLIProMetic Life SciencesC$0.00C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%CXRConcordia International0.00%0.00%0.00%0.00%0.00%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO Cannabis 0.00N/AN/AN/ACXRConcordia International 0.00N/AN/AN/AFRXForest Road Acquisition 0.00N/AN/AN/APLIProMetic Life Sciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/ACXRConcordia InternationalC$569.62M0.00N/A5.85C$6.08 per share0.00FRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/APLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/ACXRConcordia InternationalN/AC$351.680.07N/AN/AN/AN/AN/AN/AFRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/ACXRConcordia InternationalN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCNVIVO CannabisN/AN/AN/ACXRConcordia International457.022.101.66FRXForest Road AcquisitionN/A0.370.37PLIProMetic Life Sciences37.474.063.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/ACXRConcordia InternationalN/AFRXForest Road AcquisitionN/APLIProMetic Life SciencesN/AInsider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/ACXRConcordia InternationalN/AFRXForest Road AcquisitionN/APLIProMetic Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableCXRConcordia International22,50048.91 millionN/ANot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionablePLI, CXR, FRX, and ABCN HeadlinesRecent News About These CompaniesNew PLI Treatise Helps Practitioners Navigate the Complexities of Trade Secret LawOctober 3, 2024 | ipwatchdog.comIRethinking rare diseases: treat the whole patientAugust 29, 2024 | pharmaphorum.comPPanetta Institute for Public PolicyMarch 31, 2024 | scu.eduS2024 Breakthrough Prizes in Life SciencesOctober 11, 2023 | the-scientist.comTTMC Life Sciences Bhd (TMCN)July 24, 2023 | investing.comLife Sciences Learning CommunityJune 13, 2023 | slu.eduSChicago Life Sciences SummitApril 21, 2023 | bisnow.comBCollege of Liberal Arts & SciencesApril 10, 2023 | alfred.eduALabviva nets $20M Series A to ease life science procurement processMarch 27, 2023 | endpts.comETrends that will shape the life sciences industry in 2023 and beyondFebruary 24, 2023 | hindustantimes.comHPharma sector gets first tranche of payment under under PLI schemeFebruary 24, 2023 | moneycontrol.comArithmos appoints Maurizio Giraudo as Managing Director of the new Life Sciences Business Consulting UnitFebruary 21, 2023 | finance.yahoo.comWEF, Telangana joins hands to start thematic centre on healthcare and life sciencesJanuary 18, 2023 | health.economictimes.indiatimes.comWorking on PLI schemes for more sectors: Piyush GoyalSeptember 24, 2022 | retail.economictimes.indiatimes.comTSX:CVE (CENOVUS ENERGY INC.)July 30, 2021 | fool.ca Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Applied Materials' Knee-Jerk Sell-Off Is Your Signal to BuyBy Thomas Hughes | August 15, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Gold’s Explosive Rally: GDX ETF May Be the Fast Track to ProfitsBy Jeffrey Neal Johnson | September 4, 2025PLI, CXR, FRX, and ABCN Company DescriptionsVIVO Cannabis CVE:ABCNC$1.32 +0.07 (+5.60%) As of 08/3/2018ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.Concordia International TSE:CXRConcordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.ProMetic Life Sciences TSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
